Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corporate update to the ...

Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO ...

As for the Relf sisters, they received nothing. No damages, no financial compensation. Alabama offered nothing to those who ...

The Mount Sinai Hospital has performed New York City's first procedure using the HYDROS™ Robotic System, a cutting-edge technology designed to treat ...

This problem is best framed in the context of epilepsy surgery with cortical resection following SEEG ... We confirm that we have read JNNP's position on issues involved in ethical publication and ...

Avoiding overly aggressive resection that fails to address the main symptoms and ... She exhibited left ptosis, with the left eye in an abducted position and restricted adduction. Muscle strength was ...

This is highlighted by the 2013 ESGE position statement23 issued to guide European countries ... Tattooing aids the accurate marking of suspected malignant lesions and resection sites, to guide future ...

Researchers observed a link between improved overall survival and lobectomy vs. sublobar resection. Researchers are working on a long-term risk calculator with these real-world data. Among ...